Hormone replacement therapy does not appear to help dry eyes, and it may actually make them worse. A large study of postmenopausal women found that estrogen-only HRT increased the risk of dry eye syndrome by 69%, while combined estrogen-plus-progesterone therapy increased it by 29%. Each additional three years on HRT was associated with a 15% rise in risk. This is a surprising finding for many women who assume that replacing declining hormones will fix hormone-related symptoms across the board.
Why Dry Eyes Get Worse After Menopause
Dry eye disease becomes significantly more common in women as they age, and the gap between men and women widens over time. Among younger adults, the prevalence is nearly equal (about 2.9% for women versus 2.6% for men). By age 75 and older, it jumps to 22.8% in women compared to 12.6% in men. For women specifically, symptom prevalence climbs from about 14% at age 50 to 22% by age 80. One cross-sectional study found dry eye symptoms in roughly 65% of midlife women, with similar rates in perimenopausal and postmenopausal groups.
This pattern points clearly to hormonal shifts as a driving factor. Sex hormone receptors exist throughout the eye, including the glands that produce tears, the glands that produce the oily protective layer of the tear film, the cornea, and the conjunctiva. But the relationship between specific hormones and eye comfort is more complicated than “hormones drop, eyes dry out.”
The Role Estrogen and Androgens Play
The key to understanding why HRT can backfire lies in how estrogen and androgens (like testosterone) affect the eye differently. The meibomian glands, which line the edges of your eyelids and produce the oily layer that keeps tears from evaporating too quickly, respond to both hormones, but in opposite directions.
Androgens stimulate the meibomian glands. They promote oil production, help gland cells mature properly, and reduce inflammation on the eye’s surface. Estrogen, on the other hand, appears to suppress these glands. It may compete with androgens for the same receptors, effectively blocking the beneficial effects androgens would otherwise have. Estrogen also seems to inhibit oil production directly and can promote inflammation on the ocular surface. So while androgens are broadly protective for tear film quality, estrogen can undermine that protection.
This distinction matters because standard HRT formulations are designed to replace estrogen (sometimes with progesterone), not androgens. By raising estrogen levels without a corresponding boost in androgens, conventional HRT can tip the hormonal balance in a direction that’s unfavorable for the eyes.
What the Research Shows About HRT and Dry Eye Risk
The most widely cited evidence comes from a study published in JAMA that analyzed data from tens of thousands of postmenopausal women. Women using estrogen alone had a 69% higher likelihood of developing dry eye syndrome or severe symptoms compared to women not on HRT. Women on combined estrogen-plus-progesterone therapy had a 29% higher risk. The longer women stayed on HRT, the greater their risk climbed, with a consistent 15% increase for every three additional years of use.
Adding progesterone to estrogen appears to partially offset the negative effect, which aligns with the biology: progesterone may counterbalance some of estrogen’s suppressive action on the meibomian glands. But even combined therapy still carries a meaningfully elevated risk compared to no HRT at all.
One study did report a conflicting finding: women who had been on HRT for more than five years had fewer eye complaints and greater tear production than those on it for less than five years. This could suggest the eye adapts over time, or it could reflect survivor bias (women with the worst symptoms may have stopped HRT early). The overall weight of evidence still leans toward HRT increasing dry eye risk rather than resolving it.
Why the Type of Hormone Matters
Research into HRT and dry eyes is complicated by the wide variety of formulations studied. Trials have used everything from oral estradiol to transdermal patches to plant-based phytoestrogens, all at different doses. The results vary considerably depending on the specific formulation. Some meta-analyses have noted that estrogen combined with progesterone showed stronger therapeutic effects than estrogen alone, but the inconsistency across studies makes it hard to draw firm conclusions about any single product.
The delivery method (oral versus transdermal) could also matter. Oral estrogen passes through the liver and can affect the body’s hormone balance differently than a patch applied to the skin. However, there is not yet enough comparative data specifically on dry eye outcomes to say definitively that one route is safer for the eyes than another.
Testosterone as an Alternative Approach
Because androgens are the hormones that actually support the oil-producing glands in the eyelids, researchers have explored whether testosterone therapy could treat dry eyes more effectively than estrogen-based HRT. Early evidence on topical testosterone eye drops (at a concentration of 0.03%) suggests they can improve tear film stability and relieve dry eye symptoms. This approach targets the eye directly rather than changing systemic hormone levels, which could limit side effects.
Topical androgen therapy for dry eyes is still relatively new and not widely available as a standard treatment. But the biological logic is sound: if androgen deficiency is what’s actually driving meibomian gland dysfunction, then replacing androgens at the ocular surface makes more sense than raising estrogen levels systemically.
Managing Dry Eyes During and After Menopause
If you’re on HRT and experiencing worsening dry eyes, the hormones you’re taking could be a contributing factor. This doesn’t necessarily mean you need to stop HRT, especially if it’s managing other menopausal symptoms effectively, but it’s worth discussing with your prescriber so they can consider the formulation and weigh the tradeoffs.
For direct symptom relief, the standard approaches still apply: preservative-free artificial tears for daytime use, thicker gel drops or ointments at night, warm compresses to help the meibomian glands release oil, and reducing screen time or using a humidifier in dry environments. Omega-3 fatty acid supplements have shown modest benefits in some studies for tear quality, though results are mixed.
If your dry eye symptoms are severe and not responding to these measures, prescription treatments targeting inflammation on the eye’s surface can help. An eye care provider can also check whether your meibomian glands are functioning properly, since gland dysfunction (rather than simply low tear volume) is often the underlying problem in hormone-related dry eye.